DNA RNA and Cells

07 Nov 2007 Fresenius Medical Care Announces Continued Positive Data from
07 Nov 2007 Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
06 Nov 2007 Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at Society for Neuroscience Meeting
06 Nov 2007 Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology/ Association of Rheumatology Health Professionals
05 Nov 2007 Sangamo BioSciences Presents Positive Data Showing Pain Reduction by Novel ZFP Therapeutic at Society for Neuroscience Meeting
30 Oct 2007 BioAlliance Pharma's New Entity, AMEP, shows anti-angiogenic and antiproliferative activity in vitro and in vivo
26 Oct 2007 Genzyme and Sunway to Collaborate on Gene Therapy Program in China
26 Oct 2007 Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
24 Oct 2007 Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
19 Oct 2007 Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
19 Oct 2007 Aastrom Stem Cell Therapy Demonstrates Positive Results in Severe Long Bone Non-Union Fracture Trial
18 Oct 2007 Alnylam and Collaborators Publish New Pre-clinical Results on RNAi Therapeutics for the Treatment of Huntington's Disease
18 Oct 2007 Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal (TM) as a First Line Treatment for Acute Graft vs. Host Disease
12 Oct 2007 Hemispherx Biopharma Files New Drug Application for Ampligen(R)
09 Oct 2007 Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
09 Oct 2007 Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
06 Oct 2007 Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
06 Oct 2007 AVONTEC's drug candidate AVT-02 UE for the treatment of inflammatory skin diseases has entered a multiple dosing Phase I study
05 Oct 2007 Aastrom Announces Positive Interim Results From Phase I/II Study Involving Use of Vascular Repair Cells in Patients With Critical Limb Ischemia
05 Oct 2007 Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients
03 Oct 2007 Aegera Therapeutics Initiates Four Phase I/II Clinical Trials for AEG35156
02 Oct 2007 Transgene Extends Therapeutic Vaccine Candidate TG4040 Development Program Against Chronic Hepatitis C
25 Sep 2007 Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
21 Sep 2007 Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
21 Sep 2007 GenVec Technology Demonstrates Selective Anti-Cancer Activity

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top